Candriam S.C.A. Sells 129,201 Shares of Cogent Biosciences, Inc. $COGT

Candriam S.C.A. cut its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 6.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,959,168 shares of the technology company’s stock after selling 129,201 shares during the period. Candriam S.C.A. owned about 1.13% of Cogent Biosciences worth $62,962,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Cogent Biosciences during the second quarter valued at $671,547,000. Wellington Management Group LLP grew its stake in shares of Cogent Biosciences by 21.4% in the second quarter. Wellington Management Group LLP now owns 4,343,977 shares of the technology company’s stock worth $168,112,000 after purchasing an additional 765,355 shares during the last quarter. Commodore Capital LP grew its stake in shares of Cogent Biosciences by 31.5% in the first quarter. Commodore Capital LP now owns 2,888,007 shares of the technology company’s stock worth $111,159,000 after purchasing an additional 691,162 shares during the last quarter. Pictet Asset Management Holding SA grew its stake in shares of Cogent Biosciences by 18.8% in the third quarter. Pictet Asset Management Holding SA now owns 2,842,776 shares of the technology company’s stock worth $90,990,000 after purchasing an additional 449,261 shares during the last quarter. Finally, Siren L.L.C. grew its stake in shares of Cogent Biosciences by 4.9% in the first quarter. Siren L.L.C. now owns 1,709,279 shares of the technology company’s stock worth $65,790,000 after purchasing an additional 80,000 shares during the last quarter.

Cogent Biosciences Trading Up 7.0%

NASDAQ:COGT opened at $31.65 on Friday. The firm’s fifty day moving average is $31.83 and its 200-day moving average is $35.52. The company has a debt-to-equity ratio of 0.48, a quick ratio of 13.57 and a current ratio of 13.57. Cogent Biosciences, Inc. has a 52 week low of $13.93 and a 52 week high of $43.73. The firm has a market cap of $5.49 billion, a P/E ratio of -14.07 and a beta of 0.36.

Cogent Biosciences (NASDAQ:COGT – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The technology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.03). Equities analysts expect that Cogent Biosciences, Inc. will post -2.23 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on COGT shares. Guggenheim raised their target price on Cogent Biosciences from $45.00 to $52.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Wall Street Zen lowered Cogent Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, September 5th. Piper Sandler upped their price target on Cogent Biosciences from $52.00 to $55.00 and gave the company an “overweight” rating in a research report on Monday, August 17th. Wedbush reissued an “outperform” rating and issued a $55.00 price target on shares of Cogent Biosciences in a research note on Wednesday, September 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cogent Biosciences in a research report on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Cogent Biosciences currently has an average rating of “Moderate Buy” and an average target price of $51.56.

View Our Latest Stock Report on COGT

Cogent Biosciences Company Profile

(Free Report)

Cogent Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for genetically defined diseases. The company uses molecular biology and drug-discovery technologies to design therapies intended to target disease-driving mutations while limiting activity in healthy tissues.

Cogent’s lead product candidate is bezuclastinib, also known as CGT9486, an investigational, highly selective inhibitor of the KIT D816V mutation. The company is developing bezuclastinib for systemic mastocytosis, a rare disorder involving the abnormal accumulation of mast cells, including both indolent and advanced forms of the disease.

Cogent conducts its research and clinical-development activities primarily in the United States and works with clinical centers and research partners in support of its development programs.

Featured Stories

Institutional Ownership by Quarter for Cogent Biosciences (NASDAQ:COGT)

Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.